Publications by authors named "A Cornejo Donayre"
Background: Clinical end points that constitute successful treatment in severe pneumonia are difficult to ascertain and vulnerable to bias. The utility of a protocolized adjudication procedure to determine meaningful end points in severe pneumonia has not been well described.
Methods: This was a single-center prospective cohort study of patients with severe pneumonia admitted to the medical intensive care unit.
BACKGROUNDDespite guidelines promoting the prevention and aggressive treatment of ventilator-associated pneumonia (VAP), the importance of VAP as a driver of outcomes in mechanically ventilated patients, including patients with severe COVID-19, remains unclear. We aimed to determine the contribution of unsuccessful treatment of VAP to mortality for patients with severe pneumonia.METHODSWe performed a single-center, prospective cohort study of 585 mechanically ventilated patients with severe pneumonia and respiratory failure, 190 of whom had COVID-19, who underwent at least 1 bronchoalveolar lavage.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates how critical illness affects the effectiveness of β-lactam antibiotics in treating hospital-acquired pneumonia.
- Researchers analyzed plasma data from 70 patients treated with meropenem to determine how often desired pharmacokinetic/pharmacodynamic (PK/PD) goals were met.
- Results showed significant variability in meeting targets, indicating that personalized treatment strategies are necessary for critically ill patients.
Article Synopsis
- Some patients with COVID-19 develop severe pneumonia and acute respiratory distress syndrome (ARDS), prompting studies on their unique immune responses.
- Researchers analyzed lung fluid samples from COVID-19 patients and other pneumonia cases to investigate immune cell activity.
- Findings revealed that SARS-CoV-2 infects alveolar macrophages, leading to a cyclical interaction with T cells that enhances inflammation in the lungs.
Some patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop severe pneumonia and acute respiratory distress syndrome (ARDS). Distinct clinical features in these patients have led to speculation that the immune response to virus in the SARS-CoV-2-infected alveolus differs from that in other types of pneumonia. Here we investigate SARS-CoV-2 pathobiology by characterizing the immune response in the alveoli of patients infected with the virus.
View Article and Find Full Text PDF